Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

1 min read

Achieve Regulatory Excellence and Accelerate Your Clinical Trials with Veristat

Learn how Veristat’s multidisciplinary team helped sponsors navigate the complexities of global regulatory submissions, achieving early and successful outcomes.

In one case, a clinical-stage biopharmaceutical company approached us for an IND submission for an antibody therapy targeting cancer. Our team adapted to staffing challenges on the sponsor’s end, executing a flawless submission that led to FDA clearance ahead of schedule.

In another instance, we supported a biopharmaceutical company with multiregional submissions for a novel therapy targeting a rare genetic metabolic disease. By optimizing resources, Veristat experts helped secure orphan drug designations and priority reviews with both EMA and FDA.

Additionally, a small biotech developing a novel autoimmune therapy sought our expertise for a three-tiered marketing submission to FDA, MHRA, and EMA. Despite competitive pressures, our strategic approach ensured timely submissions and ongoing support.

Discover how Veristat can help you achieve regulatory success by downloading our case study today.

DOWNLOAD NOW

 

Streamline the Medical Writing Process for Simultaneous Submissions

Streamline the Medical Writing Process for Simultaneous Submissions

Veristat will streamline the medical writing process for simultaneous regulatory submissions. Learn how Veristat can help your clinical development...

Read More
IND Success Strategy: Building a High-Quality IND from Scratch with Strategic Gap Analysis

IND Success Strategy: Building a High-Quality IND from Scratch with Strategic Gap Analysis

Learn how Veristat’s regulatory team helped our sponsor without internal expertise develop, compile, and submit a complete, FDA-compliant IND...

Read More
Monthly FDA Guidance and Regulatory News Review - October 2025

Monthly FDA Guidance and Regulatory News Review - October 2025

Stay updated with Veristat's October 2025 FDA guidance and regulatory news, including new drug approvals, draft guidances, and regulatory updates...

Read More